Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000383,DXE2/Ztm,both,98 days to 56 days,24,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,33,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69666,pristane (150 ul) 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000383,DXE2/Ztm,both,98 days to 56 days,24,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,72,d,6.9402,34.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69674,pristane (150 ul) 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000383,DXE2/Ztm,both,98 days to 56 days,24,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,30,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69682,pristane (150 ul)